Menu Search
Equities

Lifecore Biomedical Inc

LDE:DUS

Lifecore Biomedical Inc

Actions
  • Price (EUR)6.00
  • Today's Change0.10 / 1.69%
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 18:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Lifecore Biomedical Inc grew revenues 24.20% from 103.27m to 128.26m while net income improved from a loss of 99.56m to a gain of 12.01m.
Gross margin34.65%
Net profit margin4.45%
Operating margin-9.20%
Return on assets2.32%
Return on equity--
Return on investment2.74%
More ▼

Cash flow in USDView more

In 2024, cash reserves at Lifecore Biomedical Inc fell by 10.63m. Cash Flow from Financing totalled 7.51m or 5.85% of revenues. In addition the company used 217.00k for operations while cash used for investing totalled 17.92m.
Cash flow per share0.4283
Price/Cash flow per share17.24
Book value per share1.28
Tangible book value per share0.6933
More ▼

Balance sheet in USDView more

Lifecore Biomedical Inc has a Debt to Total Capital ratio of 76.41%, a lower figure than the previous year's 403.51%.
Current ratio1.83
Quick ratio0.803
Total debt/total equity3.24
Total debt/total capital0.7641
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.